Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine)
Cozanitis, D.A.
Der Anaesthesist 26(12): 649-650
1977
ISSN/ISBN: 0003-2417 PMID: 603022 Document Number: 114540
Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage. It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block. However, studies into the dose necessary to combating scopolamine intoxication are indicated.
Document emailed within 1 workday
Related Documents
Cozanitis, D.A.; Toivakka, E. 1971: A comparative study of galanthamine hydrobromide and atropine-neostigmine in conscious volunteers Der Anaesthesist 20(11): 416-421Pohloudek-Fabini, R.; Jira, T. 1983: Analysis and stability of atropine sulfate and scopolamine hydrobromide. 2. Quantitative determination of the alkaloid in its decomposition product; 79. contribution to problems concerning the use of plastic containers for liquid pharmaceuticals Die Pharmazie 38(6): 390-392
Morozova, M.A.; Beniashvili, A.G.; Rupchev, G.E.; Lepilkina, T.A.; Starostin, D.S.; Brusov, O.S. 2008: Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(11): 28-35
Jira, T.; Pohloudek-Fabini, R. 1983: Analysis and stability of atropine sulfate and scopolamine hydrobromide. 3: Studies on the stability of tropane alkaloids; 80: contribution to problems in the use of plastic containers for liquid pharmaceuticals Die Pharmazie 38(8): 520-523
Bach, O.; Kästner, I. 1984: Undesired drug side effects and drug-induced damage. II. Centrally acting drugs Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 39(1): 1-6
Prozorovskiĭ, V.B.; Pavlova, L.V.; Suslova, I.M.; Shchemeleva, N.I. 1992: The pharmacological characteristics of the new anticholinesterase drug aminostigmine Eksperimental'naia i Klinicheskaia Farmakologiia 55(1): 13-16
Huidobro, F. 1971: Action of picric acid on the effects of some drugs acting on the central nervous system, with special reference to opioids Archives Internationales de Pharmacodynamie et de Therapie 192(2): 362-364
Weiss, M.; Sziegoleit, W.; Machill, K.; Hafemeister, G.; Förster, W. 1980: Relationship between the pharmacokinetics of a short-acting antiarrhythmic drug and its effects: studies with Falirytmin International Journal of Clinical Pharmacology Therapy and Toxicology 18(6): 237-241
Ono, H.; Saito, K.; Kondo, M.; Morishita, S.; Kato, K.; Hasebe, Y.; Nakayama, M.; Kato, F.; Nakamura, T.; Satoh, M. 1990: Effects of the new centrally acting muscle relaxant 7-chloro-N,N,3-trimethylbenzo[b]furan-2-carboxamide on motor and central nervous systems in rats Arzneimittel-Forschung 40(7): 730-735
Halpern, V.; Stalter, R.M.; Owen, D.H.; Dorflinger, L.J.; Lendvay, A.; Rademacher, K.H. 2015: Towards the development of a longer-acting injectable contraceptive: past research and current trends Contraception 92(1): 3-9
Yamashita, M.; Horigome, H. 1989: Echocardiographic evaluation of vagolytic effects of hyoscine butylbromide in paediatric halothane anaesthesia Agressologie 30(8): 489-491
Zhou, J.; Deng, J.; Huang, P.; Huang, C. 1998: Production of longer acting tissue plasminogen activator of humans in milk of transgenic mice Chinese Journal of Biotechnology 14(4): 221-225
Kast, A.; Tsunenari, Y.; Honma, M.; Iida, H. 1985: Cardiac effects of fenoterol hydrobromide on newborn versus adult rats Arzneimittel-Forschung 35(1a): 188-192
McKenna, K.; Arcara, J.; Rademacher, K.H.; Mackenzie, C.; Ngabo, F.; Munyambanza, E.; Wesson, J.; Tolley, E.E. 2014: Policy and programmatic considerations for introducing a longer-acting injectable contraceptive: perspectives of stakeholders from Kenya and Rwanda Global Health Science and Practice 2(4): 459-471
Tolley, E.E.; McKenna, K.; Mackenzie, C.; Ngabo, F.; Munyambanza, E.; Arcara, J.; Rademacher, K.H.; Lendvay, A. 2014: Preferences for a potential longer-acting injectable contraceptive: perspectives from women, providers, and policy makers in Kenya and Rwanda Global Health Science and Practice 2(2): 182-194
Pilz, R. 1971: Internal hospital treatment of spinal and joint diseases. Experiences with a new percutaneously acting drug Zeitschrift für Allgemeinmedizin 47(23): 1169-1172
Childs, A. 1986: Scopolamine effects in vestibular defensiveness Archives of Physical Medicine and Rehabilitation 67(8): 554-555
Drtil, M.; Vinar, O.; Taussigová, D. 1973: Maintenance treatment with long-acting neuroleptic drugs in persons with disturbances of social behavior and drug dependence Activitas Nervosa Superior 15(2): 87
Liao, W.J.; Qu, Z.W.; Zhang, J.T. 1994: Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus Yao Xue Xue Bao 29(1): 24-27
Bond, N.W. 1986: Prenatal alcohol exposure and offspring hyperactivity: effects of scopolamine and methylscopolamine Neurobehavioral Toxicology and Teratology 8(3): 287-292